Thumbnail Image
Publication

Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases

Watson, H.
; 
Cockbain, A.J.
; 
Spencer, Jade A.
; 
Race, Amanda D.
; 
Volpato, Milène
; ; 
Toogood, G.J.
; 
Hull, M.A.
Publication Date
2016-12
End of Embargo
Supervisor
Keywords
Colorectal cancer, Eicosapentaenoic acid, Omega-3 polyunsaturated fatty acid
Rights
© 2016 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
cb
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2016-10-06
Institution
Department
Awarded
Embargo end date
Collections
Life Sciences Publications
Show all metadata
Files
watson_et_al_2016.pdf
Adobe PDF, 824.95 KB
Additional title
Abstract
We investigated red blood cell (RBC) PUFA profiles, and the predictive value of RBC EPA content for tumour EPA exposure and clinical outcomes, in the EMT study, a randomised trial of EPA in patients awaiting colorectal cancer (CRC) liver metastasis surgery (A.J. Cockbain et al., 2014). There was a significant increase in RBC EPA in the EPA group (n=43; median intervention 30 days; mean absolute 1.26 [±0.14]% increase; P<0.001), but not in the placebo arm (n=45). EPA incorporation varied widely in EPA users and was not explained by treatment duration or compliance. There was little evidence of ‘contamination’ in the placebo group. The EPA level predicted tumour EPA content (r=0.36; P=0.03). Participants with post-treatment EPA ≥1.22% (n=49) had improved OS compared with EPA <1.22% (n=29; HR 0.42[95%CI 0.16–0.95]). RBC EPA content should be evaluated as a biomarker of tumour exposure and clinical outcomes in future EPA trials in CRC patients.
URI
http://hdl.handle.net/10454/10200
Version
Accepted manuscript
Citation
Watson H, Cockbain AJ, Spencer J et al (2016) Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA). 115: 60-66.
Link to publisher’s version
Link to published version
Link to Version of Record
https://doi.org/10.1016/j.plefa.2016.10.003
Type
Article
Qualification name
Notes